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Earlier studies have demonstrated overexpression of 9-O-
acetylated sialoglycoconjugates (9-O-AcSGs) on lympho-
blasts, concomitant with high titers of anti-9-O-AcSG anti-
bodies in childhood acute lymphoblastic leukemia (ALL).
Our aim was to evaluate the correlation between expression
of different 9-O-AcSGs during chemotherapeutic treatment.
Accordingly, expression of 9-O-AcSGs on lymphoblasts of
ALL patients (n  70) were longitudinally monitored for 6
years (1997–2002), using Achatinin-H, a 9-O-acetylated sialic
acid (9-O-AcSA) binding lectin with preferential affinity for
9-O-AcSGs with terminal 9-O-AcSA236GalNAc. Western
blot analysis of patients (n  30) showed that 3 ALL-specific
9-O-AcSGs (90, 120 and 135 kDa) were induced at presenta-
tion; all these bands disappeared after treatment in patients
(n  22) who had disease-free survival. The 90 kDa band
persisted in 8 patients who subsequently relapsed with reex-
pression of the 120 kDa band. FACS analysis revealed that at
presentation (n 70) 90.1 5.0% cells expressed 9-O-AcSGs,
which decreased progressively with chemotherapy, re-
mained <5% during clinical remission and reappeared in re-
lapse (80  10%, n  18). Early clearance of 9-O-AcSG cells,
during 4–8 weeks of treatment showed a good correlation
with low risk of relapse. Sensitivity of detection of 9-O-
AcSG cells was 0.1%. Numbers of both high- and low-affinity
binding sites were maximum at presentation, decreased with
treatment and increased again in clinical relapse. We pro-
pose that close monitoring of 90 and 120 kDa 9-O-AcSGs
may serve as a reliable index for long-term management of
childhood ALL and merits therapeutic consideration.
© 2004 Wiley-Liss, Inc.
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ALL is a malignant transformation of lymphoblasts and repre-
sents the single most common type of cancer in the pediatric
population. With the advent of modern chemotherapy for the
treatment of childhood ALL, virtually all patients achieve remis-
sion and approximately 80% are cured.1,2 With existing treatment
protocols, the risk of relapse remains about 20% as patients in
remission may harbor residual leukemic blasts (MRD).1 Consid-
ering the increasing numbers of new ALL cases diagnosed world-
wide,2,3 an urgent need exists to identify ALL-specific biomarkers
that are easily detectable and stably expressed the altered expres-
sion of which could be an index for reliable monitoring of ALL.
Several methods for detection of MRD are currently being tested,
but the technical expertise required and availability of specific
probes limit their widespread clinical acceptability, especially in
the developing world. Therefore, novel probes to identify unique
disease-specific molecular markers are of utmost biomedical im-
portance.
SAs, a family of 9-carbon carboxylated monosaccharides, are
important constituents of the cell membrane known to influence
many biologic reactions either by reacting with specific surface
receptors or via masking of carbohydrate recognition sites.4–7
Among the multiple variations of SA, the most frequently occur-
ring substitutions are O-acetylation at positions C-7, -8 and -9 to
form N-acetyl-7, -8 and -9-O-AcSAs, respectively, thus generating
a family of O-AcSGs. However, as O-acetyl esters from positions
C-7 and C-8 spontaneously migrate to C-9, even under physiologic
conditions, O-acetylation at C-9 is considered the most common
biologically occurring modification.
Both lectins and MAbs have been used to study sialylation
patterns.4,8–11 9-O-acetyl-GD3, considered an oncofetal marker,
has been identified using a lectin, Cancer antennarius, which
recognizes SAs that are O-acetylated at both C-4 and C-9 and
biomarkers of human melanoma.10,12 The 9-O-acetylated disialo-
syl carbohydrate sequence of CDw60 has been reported as a
marker on activated human B lymphoytes.13 A consistent decrease
of O-AcSA has been reported in a few diseases.4 9-O-acetylated
sialoglycans are detectable at low levels on human B lympho-
cytes,14 and pathologic variations have been found.15–18 However,
their detailed biologic significance, especially as potential biomar-
kers, remains obscure.
The preferential affinity of a lectin, Achatinin-H, toward termi-
nal 9-O-AcSA236GalNAc was harnessed to identify the selec-
tive presence of 9-O-AcSGs on lymphoblasts of patients with
ALL, which are minimally present on PBMCs of normal individ-
uals.5,19–23 Subsequently, we reported an enhanced level of anti-
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bodies against 9-O-AcSGs in these patients.24,25 Absence of 9-O-
AcSGs and anti-9-O-AcSGs in patients with other cross-reactive
hematologic disorders, such as CML, AML, CLL, NHL, thalasse-
mia and aplastic anemia, confirmed the specificity of these biomar-
kers.19–25
As modern treatment protocols utilize biologic and clinical
information to tailor the intensity of therapy to the risk of relapse,
using Achatinin-H as an analytic tool, the present study reports the
differential expression of 9-O-AcSGs in different phases of treat-
ment by (i) Western blotting, (ii) flow cytometry and (iii) mea-
surement of receptor density by Scatchard analysis, to assess their
correlation with disease status. Additionally, a small number of
9-O-AcSG cells were detected as MRD.
MATERIAL AND METHODS
Patients
Subjects included clinically confirmed ALL patients at presen-
tation (n  70), referred to Vivekananda Institute of Medical
Sciences (Kolkata, India) during 1997–2002. The group comprised
46 males and 24 females, the M:F ratio being 2:1; median age was
6 years (range 0.8–16) and median presenting WBC count was
12  109/l (range 0.4 to 1,000  109/l). A further 153 samples
were obtained at different stages of chemotherapy. Diagnosis was
established by cytologic examination of BM smears according to
the FAB group recommendations,26 belonging to L1 or L2, which
were immunophenotyped using antibodies against TdT, cyt-, SIg,
CD2, CD3, CD7, CD10, CD 13, CD19, CD20, CD33 and CD34.
Among cases diagnosed as ALL, immunologic subgroups were
defined as follows: common ALL (CD19, CD20, CD10, cyt-
–, SIg–; n  45), pre-B-ALL (CD19, CD20, CD10, cyt-,
SIg–; n  10) and T-ALL (CD2, CD3, CD7; n  15).
Eighteen of these 70 patients relapsed: either BM (n  8), CNS
(n  5), joint BM and CNS (n  4) or testicular (n  1).
Recurrence was demonstrated after 18, 38, 42, 52, 58, 72, 74, 87,
98, 100, 116, 138, 154, 176, 199, 211, 220 and 224 weeks of
diagnosis. Median follow-up was 36 months (range 1–84).
Children were entered into the UKALL X protocol27 with ad-
dition of further drugs, i.e., etoposide and cytosine, for intensifi-
cation. They received vincristine, daunorubicin and prednisolone
with L-asparaginase for induction. Intrathecal methotrexate was
employed with or without cranial irradiation. Followed-up patients
during maintenance therapy received intrathecal methotrexate, i.v.
vincristine, oral methotrexate and mercaptopurine. They were
broadly grouped as follows: induction of remission (phase A, 0–4
weeks), consolidation/early intensification (phase B, 4–8 weeks),
period of maintenance therapy (phase C, 8 weeks–2.5 years),
follow-up case (phase D, 2.5 years onward) and relapse (phase E).
Controls included age-matched healthy individuals (n  18) of
both sexes. All newly diagnosed ALL patients (n  70) were
divided into risk-adjusted groups according to the CCG protocol.28
Children 2–9 years of age with WBC count 10,000/ml, 10,000–
49,999/ml and 50,000/ml were classified as low-, intermediate-
and high-risk groups, respectively. Children 1–2 years of age with
WBC count 50,000/ml were placed in the intermediate-risk
group.
Venous blood (3–4 ml) or BM was collected at Vivekananda
Institute of Medical Sciences and then sent to the Indian Institute
of Chemical Biology, where PBMCs were separated by Ficoll-
Hypaque density centrifugation. Informed consent was obtained
from donors, patients and parents or guardians. The study was
approved by the Institutional Human Ethical Committee per the
protocol of the Indian Council of Medical Research.
Probe
The lectin Achatinin-H was affinity-purified from the hemo-
lymph of the African giant land snail Achatina fulica,29 which
binds preferentially to glycoconjugates having terminal 9-O-
AcSA236GalNAc derivatives.29–32 This was used as an analytic
probe for all experiments.
Western blot analysis
PBMC membranes (30 g/lane) from individual ALL patients
at different phases of treatment were electrophoresed on SDS-
PAGE (7.5%, Bio-Rad Minigel apparatus; Bio-Rad, Hercules,
CA).19,24 Proteins were transblotted on a nitrocellulose paper at
100 V for 2 hr. Membranes were blocked in TBS (0.05 M, pH 7.4)
containing 10% dsBSA (TBS-dsBSA) and probed with Achati-
nin-H (160 g/ml) in the presence of Ca2 (0.05 M). After
washing, blots were incubated at 4°C with rabbit anti-Achatinin-H
(diluted 1:500), and the antigen–antibody complex was detected
using HRP-conjugated goat antirabbit IgG (Cappel, Malvern, PA;
1:10,000).
Flow-cytometric analysis
Differential expression of 9-O-AcSGs on lymphoblasts of ALL
patients during treatment was evaluated by flow cytometry (FAC-
Scan; Becton Dickinson, Mountain View, CA) using FITC–Acha-
tinin-H and anti-CD MAbs.19,24 Briefly, cells (1  106/100 l)
from both T- and B-ALL patients in RPMI-1640 supplemented
with 2 mM glutamine, gentamycin and 10% heat-inactivated hu-
man AB serum (medium A) were blocked with goat serum (10%)
and then individually labeled with FITC–Achatinin-H or PE-con-
jugated anti-CD markers along with appropriate isotype controls
(Pharmingen, San Diego, CA) on ice for 1 hr. Cells were washed
and fixed in paraformaldehyde (1%), and binding was assessed.
PBMCs were gated for lymphocytes by staining with anti-CD45
MAb, and 98.0% positive cells were present (data not shown).
Binding of lectin and MAbs to lymphoblasts was evaluated by
both single- and double-color flow cytometry. Analysis and cal-
culations were performed using Cell Quest software (Becton Dick-
inson, San Jose, CA).
Evaluation of minimum number of 9-O-AcSG cells by flow
cytometry using FITC–Achatinin-H
To estimate the minimal number of 9-O-AcSG cells detectable
by Achatinin-H, its binding was examined using cells from T-
(MOLT4) and B- (NALM-6) ALL cell lines, which were mixed in
varying proportions with PBMCs of normal donors at ratios of 1:1,
1:10 and 1:100, keeping the total cell number constant (1  106).
In parallel, lymphoblasts of an untreated B-ALL patient (cytomor-
phologic estimate of 98% blasts) were similarly analyzed.
Scatchard analysis
PBMCs from ALL patients (2  106/150 l in each tube) at
different phases of treatment were suspended in RPMI-1640 me-
dium containing 20 mM HEPES buffer (pH 7.2) and 5 mg/ml
dsBSA. Achatinin-H was iodinated with 125I Na using the chlora-
mine T method.33 Cells were incubated with increasing doses of
125I Achatinin-H for 90 min at 4°C in the presence or absence of
a 100-fold excess of unlabeled Achatinin-H. 125I Achatinin-H-
bound cells were separated from free 125I Achatinin-H by layering
the mixture onto a 5% sucrose solution followed by centrifugation
at 12,857g for 10 min at 4°C.34 Cell-bound radioactivity in the
pellet was measured by a gamma counter. The number of receptors
per cell was extrapolated by the intersection of the curve with the
x axis, and the Kd was obtained by dividing the number of
receptors per cell by the bound/free ratio at the y axis intercept.35,36
Statistical analysis
Statistical analysis was performed using the GraphPad (San
Diego, CA) Prism statistics software program. Results are ex-
pressed as means SD for individual experiments. Student’s t-test
and ANOVA or the Mann-Whitney test were applied depending on
the normality of the sample. Reported values are 2-tailed, with p
0.05 considered statistically significant. Probabilities of survival
were calculated by the Kaplan-Meier method and statistical dif-
ferences between groups evaluated by log-rank tests.37
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RESULTS
Monitoring 9-O-AcSG expression in different phases of
treatment by western blot analysis
Differential expression of 9-O-AcSGs in ALL patients (n 30) at
different phases of treatment was demonstrated by Western blot
analysis (Fig. 1a). The presence of 3 ALL-specific 9-O-AcSGs (135,
120 and 90 kDa) was established in all patients at presentation of the
disease (phase A). At phase B, the 135 kDa band disappeared, and
only the other 2 bands (120 and 90 kDa) were observed. Subse-
quently, in phase C and later in phase D, the 120 kDa band also
disappeared. However, during follow-up there appeared to be 2 dis-
tinct patterns. The first pattern showed that, in a few patients (n 8),
the 90 kDa band remained in all phases of treatment, indicating
persistence of a minimal number of lymphoblasts expressing 9-O-
AcSG, possibly responsible for MRD; this was associated with clin-
ical relapse. In all of these relapsed patients (n 8), the 120 kDa band
reappeared along with the 90 kDa band (phase E).
In contrast, the second group of patients (n  22) consistently
showed absence of all bands including the 90 kDa band at phase
D1, indicating CCR, and good correlation with DFS. Serial mon-
itoring of the 90 kDa band from this group was critical in deter-
mining distinctions at the MRD stage. Two bands, corresponding
to 144 and 36 kDa, were consistently visible in normal donors.
Assay sensitivity was 100%.
Close association of DFS with lack of detectable 90 kDa
9-O-AcSG during clinical remission
DFS of patients was evaluated based on the presence or absence
of expression of the 90 kDa molecule during clinical remission
(Fig. 1b). Survival curves were compared using the log-rank test.
Expression of the 90 kDa molecule (n  8) consistently showed a
positive correlation with an increased probability of relapse (p 
0.001). In the cohort of 90 kDa-positive patients, all 8 relapsed
over a median observation time of 124 weeks (8–224 weeks),
whereas no relapse in the 90 kDa-negative cohort (n  22) was
observed. According to Kaplan-Meier estimation, the probability
of DFS in 90 kDa-positive patients was 0.0 at 3 years, whereas that
of 90 kDa-negative patients was 100 (Fig. 1b). These data suggest
the prognostic reliability of detecting the 90 kDa molecule during
clinical remission.
Variable expression of 9-O-AcSGs by FACS analysis
Differential expression of 9-O-AcSGs on leukemic blasts at
different phases of treatment was analyzed by flow cytometry
using FITC–Achatinin-H (Fig. 2). At presentation (phase A, n 
70), leukemic blast populations (range 40–90% as morphologi-
cally estimated) were consistently positive, with Achatinin-H
showing 90.1  5.0% 9-O-AcSG cells. Following chemother-
apy, there was a progressive decrease in the percentage of 9-O-
AcSG cells, being 12.20  5.35% in phase B (n  60) and
remaining at basal levels (5%) in phases C (n  34) and D (n 
30). Interestingly, in patients with frank relapse in phase C (n11)
and phase D (n 7), the number of 9-O-AcSG cells significantly
increased (80  10%, p  0.0067) and showed a strong positive
correlation (r  0.94) with reemergence of the 90 and 120 kDa
molecules on leukemic blasts (Fig. 1). The number of 9-O-AcSG
cells in normal individuals (n 18) was only 3.0 1.8% using the
same dose of Achatinin-H.
Status of 9-O-AcSG expression at early stage of treatment
(phase B): a possible indicator for prognosis of ALL
Based on the percentage of 9-O-AcSG cells in phase B (n 
60), patients were divided into high-risk (n  26, 5%) and
low-risk (n  34, 5%) groups (Fig. 2). DFS was monitored for
these patients during long-term chemotherapeutic treatment. Sur-
vival curves were evaluated using the log-rank test (Fig. 3a). A
positive correlation was present between the high-risk group (hav-
ing higher numbers of 9-O-AcSG cells) and increased probability
of relapse. In this group, relapses (n  18, 70%) were detected
over a median observation time of 118 weeks (8–224 weeks),
whereas there was no relapse in the low-risk group. According to
Kaplan-Meier estimation, the probability of DFS was 30 at 3 years
FIGURE 1 – (a) Representative Western blot analysis from an ALL patient at different phases of treatment. PBMC membrane fractions (30 g)
of an ALL patient at different phases of treatment and a normal donor were electrophoresed on a 7.5% SDS-PAGE gel, transferred to
nitrocellulose paper and probed with Achatinin-H. Lanes A, B, C, D, E and N represent 9-O-AcSG profiles of patients from induction of
remission, consolidation/early intensification, maintenance, follow-up and relapse as well as a normal donor, respectively. Lane D1 represents
a follow-up patient who did not relapse till the end of the period of study. (b) DFS curves of patients with ALL categorized according to
persistence or disappearance of 90 kDa 9-O-AcSG at clinical remission as evidenced by Western blotting. Patients at various follow-up time
points showed significantly poor DFS with persistence of 90 kDa 9-O-AcSG (n  8) in contrast with good DFS in patients (n  22) where 90
kDa 9-O-AcSG was absent (p  0.002). Arrow indicates the absence of the 90 kDa 9-O-AcSG band at lane D1.
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in the high-risk group and 100 in the low-risk group (Fig. 3a). The
probability of DFS was comparable to the categories set by the
CCG, relapses being 63% and 22% in high- and intermediate-risk
patients, respectively (Fig. 3b). Risk of recurrence was further
analyzed with reference to ALL lineage (Fig. 3c). There was a
significant difference in outcome between the B- and T-ALL
groups. In the high-risk group, 66% and 75% relapses were de-
tected in B- and T-ALL patients, respectively. However, according
to the categories set by the CCG, in high- and intermediate-risk
groups, the rates of relapse were 58% and 14% in B-ALL and 80%
and 50% in T-ALL patients, respectively (Fig. 3c). In both cate-
gories, T-ALL had a higher probability of relapse than B-ALL.
Taken together, these data clearly demonstrate that early monitor-
ing (phase B) of 9-O-AcSG cells using Achatinin-H may give
insight into the prognosis of ALL patients.
Sensitivity and quantitation of minimal number of 9-O-AcSG
cells using achatinin-h by FACS analysis
To simulate the in vivo scenario, the binding of Achatinin-H to
a heterogeneous cell population with different ratios of normal
PBMCS and MOLT4/NALM-6/PBMCS of a B-ALL patient was
examined (Fig. 4). In the mixed cell populations, Achatinin-H
could detect one leukemic blast in a total population of 10,3 i.e.,
0.01%; therefore, this may be considered for detection of MRD.
The percentage of blasts in these samples ranged 0.01–100%.
Differential expression of 9-O-AcSG: a potential marker for
detection of MRD
We monitored this biomarker in 58 samples of BM, peripheral
blood or both obtained from children (n 27) with ALL in clinical
remission using FITC–Achatinin-H in combination with PE anti-
bodies against established CD markers (CD19, CD10, CD7, CD3
or CD34). Expression of 9-O-AcSG and other CD markers (CD19,
CD10, CD3 and CD7) in 30 and 11 samples from B (n  15) and
T (n  5) ALL patients, respectively, showed a consistently
identical pattern of expression similar to that of normal PBMCs,
suggesting that patients were in CCR. The remaining 17 samples,
from B (n  5) and T (n  2) ALL, showed minimal levels of
9-O-AcSG, which may be indicative of MRD. These patients
subsequently relapsed, accompanied by reexpression of 9-O-Ac-
SGs along with high expression of CD10, CD19, CD3, CD7 or
CD34. A positive correlation was observed between 9-O-AcSG
FIGURE 2 – Differential expression of 9-O-AcSGs in childhood ALL
patients at different phases of treatment by FACS analysis using Achati-
nin-H as probe. Data are expressed as percentage of 9-O-AcSG cells in
leukemic blasts of an individual patient. Phases A, B, C, D and N
represent patients at induction remission (n  70), consolidation/early
intensification (n  60), maintenance therapy (n  45) and follow-up
(n  37) as well as normal donors (n 18), respectively. All patients at
phase B were divided into high-risk (n  26) and low-risk (n  34)
groups corresponding to 9-O-AcSG being5% and5%, respectively.
FIGURE 3 – (a) DFS curves of pa-
tients with ALL categorized accord-
ing to 9-O-AcSG levels at phase B
by FACS analysis. Patients at vari-
ous follow-up time points showed
significantly poor DFS with high lev-
els of 9-O-AcSG (high-risk group,
n  26), in contrast to good DFS in
the low-risk group (n  34), where
the level of 9-O-AcSG was 5%
(p  0.002). (b) DFS curves of pa-
tients with ALL categorized accord-
ing to the CCG. Patients were
grouped according to CCG criteria,28
as described in Material and Meth-
ods. Significantly poor DFS in high-
risk (n  22) and intermediate-risk
(n  18) and good DFS in low-risk
(n  20, p  0.002) groups were
observed. (c) Comparison of ALL
types according to expression of
9-O-AcSG at phase B and the CCG.
Risk groups have been separated in
B- and T-ALL patients, and percent-
ages of relapse (stippled bars) in ei-
ther lineage in individual risk groups
were compared. Open bars, patients
in clinical remission.
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and the established CD markers at presentation of the disease. In
these samples (n  17), during clinical remission, a direct com-
parison between the presence of these CD markers in combination
with 9-O-AcSG is provided in Table I, indicating the usefulness of
lectin staining for ALL monitoring. Representative profiles of
patients are shown in Figure 5, in which 78% of cells from a
T-ALL patient were CD79-O-AcSG at diagnosis. During remis-
sion, the number of these cells decreased to 4.2%. Similarly, 80% of
cells from a B-ALL patient at presentation were CD109-O-AcSG.
Following chemotherapy, only 0.42% of these cells were detected in
clinical remission (Fig. 5). Minimal levels of 9-O-AcSGs were de-
tected on cells obtained from both BM (n 11) and peripheral blood
(n  6) from patients irrespective of lineage. In general, significant
increases of the CD109-O-AcSG (70  12%) and CD79-O-
AcSG (90  8%) populations in B- and T-ALL patients correlated
well (r  0.94) with the reappearance of the 90 and 120 kDa
molecules (Fig. 1) on leukemic blasts leading to clinical relapse.
Monitoring differential expression of 9-O-AcSGs by scatchard
analysis
The observation that Achatinin-H binds to leukemic blasts of
ALL patients prompted us to study the nature of their binding by
Scatchard analysis. The binding of 125I Achatinin-H was stronger
at 4°C than at 25°C and needed approximately 60 min to achieve
saturation under the experimental conditions used. Unlabeled
Achatinin-H competed with the binding of 125I Achatinin-H, and
100-fold excess completely abolished the binding. Analysis of
binding curves revealed that the binding was biphasic at presen-
tation and relapse, indicating the existence of at least 2 types of
binding site with about a 4-fold differences in affinity (Fig. 6,
Table II). A representative Scatchard plot from a patient at pre-
sentation is shown in Figure 6. Striking differences were observed
in the number of binding sites. At presentation (n  5), large
numbers of both high-affinity (62,000/cell, low Kd) and low-
affinity (197,000/cell, high Kd) binding sites were observed. Fol-
lowing treatment, the high-affinity sites disappeared and the low-
affinity sites reduced by 66-fold. Interestingly, at relapse high-
affinity sites reappeared (11,200/cell) and low-affinity sites
increased (27,500/cell).
DISCUSSION
Interest in the use of biomarkers to evaluate future disease risk
has been greatly enhanced since they are observable end points in
disease. Assessment of the O-acetylated sialoglycan profile in ALL
is a relatively new domain in leukemia sialobiology, where the
increased presence of 9-O-AcSA have been established as an
important disease-specific determinant.5,19–25 Minimal expression
in normal healthy donors and in cross-reactive hematologic dis-
eases substantially proves that 9-O-AcSGs are novel biomarkers
unique in childhood ALL. The major achievements of the current
investigation includes the demonstration of (i) the involvement of
a unique 120 kDa molecule as an important indicator for predicting
relapse in ALL irrespective of lineage, (ii) good correlation be-
tween absence of the 90 kDa molecule during clinical remission
with DFS and (iii) a positive association between early (phase B)
clearance of 9-O-AcSG cells with reduced incidence of relapse.
The selective binding affinity of Achatinin-H allowed for the
successful detection of membrane-bound 9-O-AcSGs (Figs. 1, 2,
4–6) corresponding to 144, 135, 120, 90 and 36 kDa, which were
consistently observed at disease presentation (Fig. 1). Of these, 2
9-O-AcSGs, corresponding to 144 and 36 kDa, were constitutively
present on normal PBMCs5,19,24,25 and cannot therefore be desig-
nated as ALL-specific. However, these 2 9-O-AcSGs consistently
disappeared with initiation of chemotherapy and remained unde-
tectable 1 year after treatment or in relapse (Fig. 1); the cause of
this loss is presently not clear. Although all 5 bands possess a
similar glycotope, namely, 9-O-AcSA236GalNAc, the molecu-
lar properties of the individual sialoglycoproteins vary from each
other. Fluorimetric quantitation revealed low amounts of 9-O-
AcSA on normal PBMCs, indicating that the 36 and 144 kDa
bands are less 9-O-acetylated than the ALL-specific 9-O-AcSG.5,19
Earlier reports also suggested that both the 36 and 144 kDa forms
are less immunogenic, as evidenced by reduced complement-
mediated cell lysis.24,25
Of the 3 ALL-specific molecules corresponding to 135, 120 and
90 kDa, only the 90 kDa band persisted during clinical remission
in patients who relapsed (n  8), suggesting its potential applica-
tion for monitoring of MRD (Fig. 1b). The absence of the 90 kDa
molecule in phase D correlated (100%) with DFS, reinforcing the
prognostic value of this molecule.
The disappearance of the 120 kDa band as early as 8 weeks of
treatment and its continued absence during clinical remission
suggest its utility in evaluating disease status. Early clearance of
leukemic cells is reported to have a favorable prognostic rele-
vance;38 therefore, close monitoring of the 120 kDa molecule
using Achatinin-H/anti-120 kDa MAb by FACS analysis is ex-
pected to be highly beneficial in the prediction of relapse. Rein-
duction of the 120 kDa band in phase E clearly indicates its
potential for prediction of relapse during maintenance therapy. We
therefore propose that critical examination of these 2 newly in-
FIGURE 4 – Dilution experiment showing sensitivity for detection of
MRD. Leukemic blasts of an untreated patient of B-ALL, MOLT-4 or
NALM-6 were mixed with PBMCs of normal donors in various
proportions. For each combination, 9-O-AcSG cells were analyzed
by FACS using FITC–Achatinin-H. The x axis represents the percent-
age of admixed blast cells. The percentage of 9-O-AcSG blasts
represents the mean of triplicates and is plotted on the y axis.
TABLE I – COMPARISON OF COMBINATION OF ACHATININ-H STAINING
WITH THAT OF ESTABLISHED CD MARKER BY FACS ANALYSIS FOR
MONITORING ALL PATIENTS DURING CLINICAL REMISSION
MAb/lectin combination Frequency of application1
CD19–Achatinin-
H
12 (60%)
CD10–Achatinin-
H
9 (45%)
CD19–CD10 6 (30%)
CD19–CD34 5 (25%)
CD7–Achatinin-H 5 (100%)
CD5–Achatinin-H 3 (60%)
CD7–CD5 2 (40%)
1Percentages of samples with B- and T-ALL followed using PE–
anti-CD MAbs or FITC–Achatinin-H, respectively.
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duced antigens may provide an efficient tool for universal moni-
toring of MRD, potentially applicable for designing patient-spe-
cific chemotherapy of childhood ALL.
Analytic methods for quantification of these alkali-labile O-
AcSGs are prone to error,39 and substantial loss of this O-acety-
lation during membrane preparation was reported earlier.18 There-
fore, accurate determination of these saponifiable groups, in the
proper sterical context, on the intact cell surface is feasible only by
noninvasive approaches, such as FACS analysis with lectins (Fig.
2) or use of antibodies as probes.19,24,25
FACS analysis showed a higher degree of Achatinin-H binding
at presentation compared to patients in clinical remission (Fig. 2).
This corroborated with enhanced expression of the 135, 120 and 90
kDa molecules before treatment, whereas minimal binding of
Achatinin-H during remission was possibly due to the persistent 90
kDa molecules. The sharp increase in 9-O-AcSG cells with
clinical relapse was in agreement with the reappearance of the 120
kDa band in Western blots. Patients belonging to the high-risk
group in phase B exhibited poorer DFS than those in the low-risk
group (Fig. 3a). Patients in the low-risk group did not relapse even
after 3 years (Fig. 3a). Hence, our results suggest that measure-
ment of 9-O-AcSG cells at phase B can be utilized for prognostic
evaluation.
Single-color FACS analysis using Achatinin-H was corrobo-
rated by double-color analysis (Fig. 5), wherein the high expres-
sion of 9-O-AcSG concomitant with expression of CD10,
CD19, CD3, CD7 or CD34 was used as a measure of
circulating lymphoblasts of B- and T- ALL. However, minimal
presence (5%) of such cells at clinical remission may be con-
sidered MRD as supported by clinical parameters (Fig. 5).
Identification of MRD by their morphologic features is subjec-
tive and lacks sensitivity mainly due to the limited number of
specific CD markers used for routine immunophenotyping. So far,
progress in the identification of new leukemia-specific markers has
relied on testing the expression of known CD markers, e.g., Tdt,
CD66, CD58, CD45, CD34, CD19, CD20, CD22, CD10, CD3,
CD5, etc., which is largely based on trial and error and is
slow.3,40–42 As experienced in BIOMED Concerted Action on
MRD, using different triple combinations of antibodies (CD10–
CD20–CD19, TdT–CD10–CD19, TdT–CD5–CytCD3), sensitiv-
ity of 10–4 in 82% and 10–5 in 12% of the samples was reported.42
Detection of MRD with a sensitivity of 0.01–1.13% has been
FIGURE 6 – Scatchard analysis of 9-O-AcSG receptors present on
mononuclear cells from ALL patients. Cells (2  106/tube) suspended
in RPMI-1640 medium were incubated for 90 min at 4°C with varying
doses of 125I Achatinin-H. Specificity of binding was determined in
parallel competition experiments using a 100-fold excess of unlabeled
Achatinin-H. To determine specific binding, the nonspecific binding
(obtained from 100-fold excess of unlabeled Achatinin-H in the pres-
ence of the same amount of 125I Achatinin-H used in binding to
PBMCs) was subtracted from the total binding of 125I Achatinin-H. Kd
values and numbers of Achatinin-H binding sites per cell were derived
from Scatchard analysis. Data are means of 3 independent experiments
from a patient at presentation.
FIGURE 5 – Differential expression
of 9-O-AcSG cells using FITC–
Achatinin-H by double-color FACS
analysis. Representative profiles of
BM cells from 2 ALL children of T-
and B- lineages are shown at diag-
nosis (left panels) and at the end of
remission-induction therapy (middle
panels, i.e., when patients were at
complete morphologic remission)
along with a normal donor (right pan-
els). Flow-cytometric dot plots illus-
trate expression of 9-O-AcSGCD7
and 9-O-AcSGCD10 cells in T-
and B-ALL patients, respectively.
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observed using anti-CD58 antibody.41 Achatinin-H is capable of
detecting 0.1–1% leukemic cells by identifying 9-O-AcSG cells
as a measure of MRD (Fig. 4). This assay gave a sensitivity of 10–3
in 60% of total samples from both B- and T-ALL patients. How-
ever, in 29% of the total cases, sensitivity was 10–4 and maximum
sensitivity, under these circumstances, was 10–5 in 11% of the total
cases. It may be possible to further increase the level of sensitivity,
in most patients, using Achatinin-H along with different triple
combinations of anti-CD antibodies.
Use of peripheral blood to detect MRD is debatable42 as 2 recent
studies43,44 have shown that paired MRD values in BM and pe-
ripheral blood are highly concordant in T-ALL. Conversely, large
differences frequently occur in B-ALL, where levels are much
higher in BM than in peripheral blood. Thus, there are different
amounts of ALL cells of different lineages in blood after treatment
as measured by known CD markers. However, Achatinin-H is able
to consistently detect 9-O-AcSGs, as an ALL-specific marker, in
both peripheral blood and BM irrespective of lineage (Figs. 2, 5).24
However, larger trials are needed to establish whether peripheral
blood investigation can substitute for BM analysis. Achatinin-H
along with antibodies against the 90 and 120 kDa bands can serve
as new armaments in ALL research.
Differential expression of 9-O-AcSGs was reflected in the Scat-
chard analysis (Table II). It was consistently observed that there
were large numbers of both high- and low-affinity receptors at
disease presentation, very low levels of low-affinity binding sites
during clinical remission and increased levels of both during
relapse. Therefore, the 120 and 90 kDa molecules may be associ-
ated with the high- and low-affinity receptors, respectively; how-
ever, the variations of Kd in different phases of treatment are
difficult to explain in terms of discrete molecular entities.
O-Acetylation of sialoglycoconjugates depends primarily on
O-acetyltransferases and possibly on sialyltransferases. Homeosta-
sis of these enzymes, responsible for the resultant expression of
O-acetyl derivatives, may become perturbed during medication,
giving rise to differential effects on different 9-O-AcSGs and
accounting for slight variations in Kd values. In future, it will be
important to determine the role of fine-tuning these enzymes in
disease conditions. However, measurement of O-acetyltransferase
activity is extremely difficult,45 though the substrate specificity and
subcellular localization of this enzyme in normal human colonic
mucosa have been demonstrated.46
Modification of cell surface sialyl residues can be correlated to
a differentiation marker in developmental processes and protection
against sialidases.4,5,47 However, the relationship between 9-O-
acetylation of SAs during neoplastic transformation and immune
system abnormalities remains poorly understood. 9-O-acetylation
is known to abrogate the normal functions of SAs in preventing the
activation of alternate complement pathways due to involvement
of the exocyclic side chain of SA. 9-O-AcSGs on erythrocytes of
patients suffering from visceral leishmaniasis are potent comple-
ment activators that cause enhanced hemolysis.48 Interestingly,
derivatives of the exocyclic side chain of SA are also important
determinants of Achatinin-H binding.29 The ligand of human B-
cell adhesion molecule (CD22) is a ubiquitously present glycotope
with 2-6 linked SA, and it has been postulated that 9-O-AcSGs
play a regulatory role, preventing undesirable CD22-mediated
interactions with inappropriate targets through this moiety.49
Hence, the increased expression of 9-O-AcSGs on lymphoblasts
hinders the cascade of CD22-mediated cellular interactions by
masking their binding sites, which is also the epitope of Achatinin-
H,29,30,32 thereby influencing cell adhesion-dependent immune re-
sponses. Therefore, it is reasonable to hypothesize that the in-
creased O-acetylation may well be an effective strategy adopted by
leukemic blasts to circumvent immune surveillance.
In summary, our results indicate that the 90 and 120 kDa
molecules are 2 novel lymphoblastoid antigens, which would
allow the design of disease-specific primers for detection of MRD
and may help in the development of new therapeutic strategies.
The availability of MAbs against these molecules is expected to be
useful for immunophenotyping and drug targeting in ALL.
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